Atopic dermatitis (AD) is a chronic pruritic inflammatory skin disease with an increasing prevalence. Although the etiology of AD is not completely understood, numerous studies suggest that impaired skin barrier function and immune dysregulation underlie the disease. We have developed novel allergen-inducible and spontaneous mouse models that mimic human AD: AD-like skin lesions induced by epicutaneous treatment with allergen require mast cells and the receptor for thymic stromal lymphopoietin (TSLP). We found that phospholipase C (PLC)-?3-deficient mice spontaneously develop AD-like skin lesions with increased expression of TSLP and periostin in a mast cell-dependent manner;allergen-induced dermatitis was more severe in PLC-?3-/- than in wild-type mice. Gene expression profiles in lesional skin exhibited high similarity between allergen-induced dermatitis, spontaneous dermatitis in PLC-?3-/- mice, and human AD. We recently reported that PLC-?3 inhibits the proliferation of hematopoietic cells, including mast cells, through formation of the multi-molecular SPS complex containing SHP-1 (protein phosphatase), PLC-?3, and Stat5 (transcription factor);PLC-?3 interacts with SHP-1 and Stat5, augments the dephosphorylating activity of SHP-1 toward Stat5, and inhibits Stat5 activity. Stat5 and Jak2 (a Stat5-activating kinase) are essential for the development and proliferation of mast cells. Our preliminary data indicated the involvement of mast-cell Stat5 and SHP-1 in AD pathogenesis, as revealed by reduced or enhanced severity of allergen-induced dermatitis in mice with mast cell-specific deletion of Stat5 or SHP-1, respectively, as well as strong efficacy of a Jak-Stat5 inhibitor to prevent allergen-induced dermatitis. Moreover, human AD skin had increased numbers of mast cells with high activation levels of STAT5 and the genes encoding the SPS components were linked to the risk of human AD and/or its severity. These and other preliminary data have led to the following hypotheses: (1) The Stat5- regulatory pathway in mast cells plays a critical pathogenic role in AD. (2) SPS components regulate the activity of the cellular elements of the dermatitis-amplifying/perpetuating vicious cycle consisting of Th2 cytokines (mast cells), periostin (fibroblasts), and TSLP (keratinocytes). (3) The SPS components regulate not only mouse, but also human mast cell biology. Therefore, (Aim 1) using conditional knockout mice of SPS component genes as well as pharmacological approaches, we will further evaluate the role of the mast cell Stat5-regulatory pathway in development and persistence of dermatitis in PLC-?3-/- mice.
(Aim 2) Using in vitro cultures and in vivo models, we will study how SPS components regulate Th2 cytokine production from mast cells, periostin production from fibroblasts, and TSLP production from keratinocytes.
(Aim 3) Finally, we will study the role of SPS components in the growth, survival, and Fc?RI (high-affinity IgE receptor)-mediated activation of human mast cells and compare mast cells between human AD and healthy individuals. Overall, this project will likely establish a novel paradigm of AD pathogenesis and provide a novel therapeutic strategy.
The prevalence of atopic dermatitis and other allergic diseases has been dramatically increasing for the last few decades. Up to 20% of children and ~3% adults suffer from atopic dermatitis. However, no treatment is preventive or curative. Although most patients respond to steroids and calcineurin inhibitors (tacrolimus and pimecrolimus), these drugs have side effects and there are recalcitrant cases to the treatment. Thus, novel therapeutics are urgently needed. This project will not only establish a new paradigm of the etiology and pathogenesis of atopic dermatitis, but also will provide novel innovative therapeutic strategies.
|Kawakami, Yu; Sielski, Rachel; Kawakami, Toshiaki (2018) Mouse Body Temperature Measurement Using Infrared Thermometer During Passive Systemic Anaphylaxis and Food Allergy Evaluation. J Vis Exp :|
|Herro, Rana; Shui, Jr-Wen; Zahner, Sonja et al. (2018) LIGHT-HVEM signaling in keratinocytes controls development of dermatitis. J Exp Med 215:415-422|
|Kawakami, Yuko; Ando, Tomoaki; Lee, Jong-Rok et al. (2017) Defective natural killer cell activity in a mouse model of eczema herpeticum. J Allergy Clin Immunol 139:997-1006.e10|
|Ando, Tomoaki; Kashiwakura, Jun-Ichi; Itoh-Nagato, Naoka et al. (2017) Histamine-releasing factor enhances food allergy. J Clin Invest 127:4541-4553|
|Wang, Zhenping; Mascarenhas, Nicholas; Eckmann, Lars et al. (2017) Skin microbiome promotes mast cell maturation by triggering stem cell factor production in keratinocytes. J Allergy Clin Immunol 139:1205-1216.e6|
|Sidler, Daniel; Wu, Ping; Herro, Rana et al. (2017) TWEAK mediates inflammation in experimental atopic dermatitis and psoriasis. Nat Commun 8:15395|
|Kawakami, Toshiaki; Blank, Ulrich (2016) From IgE to Omalizumab. J Immunol 197:4187-4192|
|Draber, Petr; Halova, Ivana; Polakovicova, Iva et al. (2016) Signal transduction and chemotaxis in mast cells. Eur J Pharmacol 778:11-23|
|Marichal, Thomas; Gaudenzio, Nicolas; El Abbas, Sophie et al. (2016) Guanine nucleotide exchange factor RABGEF1 regulates keratinocyte-intrinsic signaling to maintain skin homeostasis. J Clin Invest 126:4497-4515|
|Kawakami, Toshiaki; Ando, Tomoaki; Kawakami, Yuko (2015) Hypothetical Atopic Dermatitis-Myeloproliferative Neoplasm Syndrome. Front Immunol 6:434|
Showing the most recent 10 out of 14 publications